»ùÒò±à¼ÓÃøµÄ¶¨ÖÆ¿ª·¢
ЧÀÍÏêÇé
| Ó¦ÓÃÁìÓò | 1¡¢»ùÒò±à¼ 2¡¢CRISPR¼ì²â |
|---|---|
| ÖÜÆÚ/¼ÛÇ® |
¿ìÖÁ1ÖÜ£¬£¬£¬£¬£¬3800ÔªÆð |
ЧÀÍÓÅÊÆ
¶àÄê»ùÒò±à¼ÂÄÀú
¶àÄêCRISPR¼ì²âÂÄÀú
½»¸¶ÎÞа
¼¼Êõõè¾¶
ÒÑ¿ª·¢²úÆ·ÖÖÀà/ÀàÐÍ
| Spcas9 | Lbcas12a | Aapcas12b | Lbucas13a | Lwacas13a | |
|---|---|---|---|---|---|
| PAM/PFS | 5’-NGG-3’ | 5’-TTTV-3’ | 5’-TTN-3’ | None | None |
| None | dsDNA | dsDNA or ssDNA | dsDNA or ssDNA | ssRNA | ssRNA |
| Cis-cleavage | dsDNA | dsDNA or ssDNA | dsDNA or ssDNA | ssRNA | ssRNA |
| Trans-cleavage | None | ssDNA | ssDNA | ssRNA | ssRNA |
Êý¾Ý°¸Àý
ͨ¹ý»îÐÔ²âÊÔ£¬£¬£¬£¬£¬±ÈÕÕÍêÃÀÕæÈËÌṩµÄ»ùÒò±à¼ÓÃøÓ뾺ƷµÄÐÔÄÜ¡£¡£¡£¡£¡£¡£
·´Ó¦ÏµÍ³ÖÐÌí¼Ó´ý¼ìTargetÄ£°å¡¢Casø¡¢crRNAºÍÓ«¹â̽Õ룬£¬£¬£¬£¬µ±crRNAÓëCasø×é×°ÀÖ³ÉÄܸ´ºÏÎﲢʶ±ðTargetÄ£°åºó£¬£¬£¬£¬£¬»á¼¤»îCasøµÄ·´Ê½Çиî»îÐÔ²¢ÇиîÓ«¹â̽ÕëÊͷųöÓ«¹âÐźţ¬£¬£¬£¬£¬Í¨¹ýÓ«¹âÖµÀ´·´Ó¦Ã¸µÄÐÔÄÜ¡£¡£¡£¡£¡£¡£×óͼºÍÓÒͼÊÇ»®·ÖÕë¶ÔLbucas12aºÍLwacas3aÁ½ÖÖø¾ÙÐвâÊÔ£¬£¬£¬£¬£¬Ð§¹ûÏÔʾ£¬£¬£¬£¬£¬ÍêÃÀÕæÈËÌṩµÄøµÄÓ«¹âÇ¿¶È¸üÇ¿£¬£¬£¬£¬£¬Çиî»îÐÔÓëѸËÙÐÔÏÔןüÓÅ¡£¡£¡£¡£¡£¡£


Advantage and Characteristic
Optimazied Strategy
Optimazied Strategy
Optimazied Strategy
Optimazied Strategy
¾«Ñ¡¿Í»§ÎÄÕÂ
Deep whole-genome analysis of 494 hepatocellular carcinomas
È«ÇòÁè¼ÝÒ»°ëµÄ¸Îϸ°û°©£¨HCC£©²¡Àý±¬·¢ÔÚÖйú£¬£¬£¬£¬£¬µ«ÏÖÔÚÕë¶ÔÖйúÈËȺÖÐÒÒÐ͸ÎÑײ¡¶¾£¨HBV£©Ïà¹ØHCCµÄÈ«»ùÒò×éÆÊÎöÑо¿ºÜÊÇÓÐÏÞ¡£¡£¡£¡£¡£¡£ÎªÁËÍ»ÆÆÕâÖÖÏÞÖÆ£¬£¬£¬£¬£¬Ñо¿Ö°Ô±Æô¶¯ÁË“Öйú¸Î°©Í¼Æ×ÏîÄ¿”£¨CLCA£©£¬£¬£¬£¬£¬Ö¼ÔÚ¶ÔÖйúÈËȺÖеÄHCC¾ÙÐдó¹æÄ£µÄÈ«»ùÒò×éÆÊÎöÒÔÃ÷È·ÆäÆæÒìµÄ·¢²¡»úÖÆºÍ½ø»¯Àú³Ì¡£¡£¡£¡£¡£¡£¸ÃÏîÄ¿¶Ô494ÀýHCCÖ×ÁöÑù±¾¾ÙÐÐÁËÉî¶ÈÈ«»ùÒò×é²âÐò£¨Æ½¾ù²âÐòÉî¶ÈΪ120×£©£¬£¬£¬£¬£¬²¢ÆÊÎöÁËÆ¥ÅäµÄ±ÈÕÕѪҺÑù±¾£¬£¬£¬£¬£¬Õ¹ÏÖÁËHBVÏà¹ØHCCµÄÏêϸ»ùÒò×éÌØÕ÷¡£¡£¡£¡£¡£¡£Ñо¿·¢Ã÷£¬£¬£¬£¬£¬³ýÁËÒÑÖªµÄ±àÂëÇøÇý¶¯»ùÒò£¨ÈçTP53ºÍCTNNB1£©Í⣬£¬£¬£¬£¬»¹±£´æ6¸öеıàÂëÇøÇý¶¯»ùÒò£¨°üÀ¨FGA£©ºÍ31¸ö·Ç±àÂëÇøÇý¶¯»ùÒò¡£¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬Ñо¿»¹Õ¹ÏÖ5ÖÖеÄÍ»±äÌØÕ÷£¨°üÀ¨SBS_H8£©£¬£¬£¬£¬£¬ÒÔ¼°HBVÕûºÏÐγÉϸ°ûÍâ»·×´DNA£¨ecDNA£©µÄÕ÷Ï󣬣¬£¬£¬£¬ÕâЩecDNA¿Éµ¼Ö°©»ùÒòÀ©ÔöºÍ±í´ïÔöÌí¡£¡£¡£¡£¡£¡£Í¨¹ý¹¦Ð§Ñé֤ʵÑ飬£¬£¬£¬£¬Ñо¿Ö°Ô±Ö¤ÊµÁËFGA¡¢PPP1R12BºÍKCNJ12µÈ»ùÒòµÄÍ»±äÄܹ»ÏÔÖøÓ°ÏìHCCϸ°ûµÄÔöÖ³¡¢Ç¨áãºÍÇÖÏ®ÄÜÁ¦¡£¡£¡£¡£¡£¡£ÕâÏîÑо¿Ð§¹û²»µ«¸»ºñÁËÈËÃǶÔHCC»ùÒò×éѧµÄÃ÷È·£¬£¬£¬£¬£¬Ò²ÎªHCCµÄÕï¶ÏºÍÖÎÁÆÌṩÁËеÄDZÔڰе㡣¡£¡£¡£¡£¡£

ºòÑ¡Çý¶¯Òò×Ӹſö
Targeted Macrophage CRISPR-Cas13 mRNA Editing in Immunotherapy for Tendon Injury
¼¡ëìËðÉ˼±ÐÔÑ×Ö¢ÆÚÖУ¬£¬£¬£¬£¬¾ÞÊÉϸ°ûÌ«¹ý¼¤»î»áµ¼Ö±àÂë¹ÇÇÅÂѰ×OPNµÄSPP1¹ý±í´ï£¬£¬£¬£¬£¬Ó°Ïì×éÖ¯ÔÙÉú¡£¡£¡£¡£¡£¡£CRISPR-Cas13ÓÉÓÚ¾ßÓÐRNA±à¼ºÍ¿ìËÙ½µ½âµÄÄÜÁ¦£¬£¬£¬£¬£¬ÔÚ×éÖ¯ÐÞ¸´·½Ãæ¾ßÓÐÖØ´óDZÁ¦£¬£¬£¬£¬£¬µ«È±·¦ºÏÊÊÓÐÓõĵÝËÍÒªÁì¡£¡£¡£¡£¡£¡£¶Ô´Ë£¬£¬£¬£¬£¬Ñо¿Ö°Ô±ÏµÍ³É¸Ñ¡ÁËÕë¶Ô¾ÞÊÉϸ°ûµÄÑôÀë×Ó¾ÛºÏÎ£¬£¬£¬£¬¿ª·¢ÁËÒ»ÖÖÄܹ»¸ßЧµÝËÍCas13ºËÌǺËÂѰ׸´ºÏÎCas13 RNP£©½øÈë¾ÞÊÉϸ°ûµÄÄÉÃ×´ØÔØÌå¡£¡£¡£¡£¡£¡£Í¨¹ý·´Ó¦ÐÔÑõÖÖ£¨ROS£©ÏìÓ¦ÐÔÊÍ·Å»úÖÆ£¬£¬£¬£¬£¬¸ÃϵͳÄܹ»ÔÚ¼¡ëìËðÉ˵ļ±ÐÔÑ×֢΢ÇéÐÎÖÐÌØÒìÐÔÒÖÖÆ¾ÞÊÉϸ°ûÖÐSPP1µÄ¹ý±í´ï¡£¡£¡£¡£¡£¡£ÊµÑéЧ¹ûÅú×¢£¬£¬£¬£¬£¬ÕâÖÖ°ÐÏò²ßÂÔÏÔÖøïÔÌÁËËðÉËÓÕµ¼µÄSPP1±¬·¢¾ÞÊÉϸ°ûµÄ·ºÆð£¬£¬£¬£¬£¬½µµÍÁ˳ÉÏËάϸ°ûµÄ¼¤»î£¬£¬£¬£¬£¬²¢¼õÇáÁ˼¡ëìÖÜΧµÄÕ³Á¬Ðγɡ£¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬¸ÃÑо¿»¹Õ¹ÏÖÁËSPP1ͨ¹ýCD44/AKTÐźÅͨ·Ôö½ø³ÉÏËάϸ°û»î»¯ºÍǨáãµÄ»úÖÆ£¬£¬£¬£¬£¬²¢Í¨¹ýÒÖÖÆÕâһͨ·ÓÐÓûº½âÁ˼¡ëìËðÉ˺óµÄÕ³Á¬ÎÊÌâ¡£¡£¡£¡£¡£¡£

ÓÃÓÚPAÖÎÁƵľÞÊÉϸ°ûÃâÒß΢ÇéÐ줻îmRNA±à¼²ßÂÔµÄʾÒâͼ
Electrical stimulation of piezoelectric BaTiO3 coated Ti6Al4V scaffolds promotes anti-inflammatory polarization of macrophage and bone repair via MAPK/JNK inhibition and OXPHOS activation
¼¹ËèËðÉË£¨SCI£©ÊÇÒ»ÖÖµ¼Ö¸ÐÊÜ×ÔÖ÷Éñ¾ºÍÔ˶¯¹¦Ð§µÄÓÀÊÀÐÔË𺦵ÄÑÏÖØÖ²ÐÐÔ¼²²¡¡£¡£¡£¡£¡£¡£¸Éϸ°ûÁÆ·¨£¬£¬£¬£¬£¬ÓÈÆäÊǼä³äÖʸÉϸ°û£¨MSCs£©£¬£¬£¬£¬£¬ÔÚSCIÖÎÁÆÖÐÕ¹ÏÖ³öÖØ´óDZÁ¦µ«ÆäÔÙÉúÄÜÁ¦ÓÐÏÞ£¬£¬£¬£¬£¬ÕâÏÞÖÆÁËÆäÔÚ×éÖ¯ÔÙÉúÖеÄÓ¦Óᣡ£¡£¡£¡£¡£Ñо¿ÍŶÓÊӲ쵽ABPCsÑÜÉúµÄEVs£¨EVsABPC£©¿ÉÄÜЯ´øÔö½ø×éÖ¯ÔÙÉúµÄÉúÎï»îÐÔÐźţ¬£¬£¬£¬£¬Òò´ËËûÃÇ´Ó¹½ÇÑ¿»ù×æÏ¸°û£¨ABPCs£©ÖÐÌáÈ¡²¢ÐÞÊÎÁËϸ°ûÍâÄÒÅÝ£¨EVsABPC£©£¬£¬£¬£¬£¬²¢½«ÆäÓ¦ÓÃÓÚ¼¹ËèËðÉË£¨SCI£©µÄÖÎÁÆÑо¿¡£¡£¡£¡£¡£¡£Ñо¿Ö°Ô±·¢Ã÷EVsABPCÄܹ»ÏÔÖøÔöÇ¿Éñ¾¸Éϸ°û£¨NSCs£©µÄÔöÖ³£¬£¬£¬£¬£¬Ôö½øÖáÍ»Éú³¤£¬£¬£¬£¬£¬ïÔÌÉñ¾ÔªµòÍö£¬£¬£¬£¬£¬²¢Í¨¹ýµ÷ÀíÑ×Ö¢·´Ó¦½«¾ÞÊÉϸ°û´Ó´ÙÑ×µÄM1Ðͼ«»¯Îª¿¹Ñ×µÄM2ÐÍ¡£¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬¾Óɹ¤³Ì»¯Ë¢ÐµÄEVsABPC£¨Í¨¹ý¼¤»îϸ°û´©Í¸ëÄÐÞÊΣ©Äܹ»¸üÓÐÓõذÐÏòSCIËðÉ˲¿Î»£¬£¬£¬£¬£¬ÏÔÖø¸ÄÉÆÉñ¾ÔÙÉúºÍÔ˶¯¹¦Ð§»Ö¸´¡£¡£¡£¡£¡£¡£ÕâЩЧ¹ûÅú×¢£¬£¬£¬£¬£¬EVsABPCÊÇÒ»ÖÖ¼«¾ßDZÁ¦µÄSCIÖÎÁƺòÑ¡¼Æ»®¡£¡£¡£¡£¡£¡£

ͼ½âÕªÒª
Generation of recombinant antibodies by mammalian expression system for detecting S-metolachlor in environmental waters
S-Òì±û¼×²Ý°·£¨S-MET£©ÊÇÎÒ¹úÉú²úºÍʹÓÃÁ¿×î´óµÄ³ý²Ý¼ÁÖ®Ò»£¬£¬£¬£¬£¬Æä»¯Ñ§ÌØÕ÷µ¼ÖÂÆä¿ÉÔÚÍÁÈÀÖг¤ÆÚ±£´æÒÔ¼°ÈÝÒ×ͨ¹ýÁÜÈܺͳÁ½µÎÛȾµØ±íË®ºÍµØÏÂË®£¬£¬£¬£¬£¬×îÖÕÓ°ÏìÖ²ÎïÉú³¤ºÍͨ¹ýʳÎïÁ´Î£º¦ÈËÀàÉúÃü¿µ½¡¡£¡£¡£¡£¡£¡£¼øÓÚÏÖÓмì²âÒªÁìµÄ¾ÖÏÞÐԺͶԸßЧÆÊÎö¼¼ÊõµÄÆÈÇÐÐèÇ󣬣¬£¬£¬£¬¸ÃÑо¿ÒÔS-metolachlorΪ¹¤¾ß£¬£¬£¬£¬£¬Ê¹Óò¸È鶯Îï±í´ïϵͳÌìÉúÏà¹ØÖØ×鿹Ìå¡£¡£¡£¡£¡£¡£ÔÚÀֳɱí´ï¿¹ÌåµÄ»ù´¡ÉÏ£¬£¬£¬£¬£¬Àֳɽ¨ÉèÁË»ùÓÚÕâЩ¿¹ÌåµÄÃâÒ߯ÊÎöÒªÁ죬£¬£¬£¬£¬ÓÃÓÚ¼à²âÇéÐÎË®ÑùÖеÄS-Òì±û¼×²Ý°·²ÐÁô¡£¡£¡£¡£¡£¡£icELISAЧ¹ûÏÔʾ£¬£¬£¬£¬£¬ÖØ×鿹ÌåµÄѸËٶȺÍÌØÒìÐÔÓëÇ×±¾µ¥¿¹ÏàËÆ£¬£¬£¬£¬£¬¿É¼á³ÖÔÓеÄÉúÎïѧ»îÐÔ£¬£¬£¬£¬£¬¹ØÓڽˮ¡¢Å©ÌïË®ºÍ×ÔÀ´Ë®ÖеÄS-MET£¬£¬£¬£¬£¬¾ßÓÐÓÅÒìµÄ׼ȷÐÔºÍÖØ¸´ÐÔ¡£¡£¡£¡£¡£¡£

ͼ½âÕªÒª
Dumbbell probe initiated multi-rolling circle amplification assisted CRISPR/Cas12a for highly sensitive detection of clinical microRNA
ϸСRNA£¨miRNA£©ÊÇÒ»ÀàСµÄ·Ç±àÂëRNA·Ö×Ó£¬£¬£¬£¬£¬Í¨¹ýÓëÌØ¶¨°Ð»ùÒòµÄÐÅʹRNA£¨mRNA£©Ï໥×÷ÓÃÀ´µ÷¿Ø»ùÒò±í´ï¡£¡£¡£¡£¡£¡£miRNAÔÚ¶àÖÖ¼²²¡µÄ±¬·¢¡¢Éú³¤Àú³ÌÖÐÊÎÑÝ×ÅÖ÷Òª½ÇÉ«£¬£¬£¬£¬£¬±»ÒÔΪÊǼ«¾ßDZÁ¦µÄ¼²²¡ÉúÎï±ê¼ÇÎï¡£¡£¡£¡£¡£¡£¸ÃÑо¿Ê¹ÓÃCRISPR/Cas12a¿ª·¢ÁËÒ»ÖÖΪDBmRCAµÄÐÂÐÍmiRNA¼ì²â¼¼Êõ¡£¡£¡£¡£¡£¡£¸Ã¼¼ÊõʹÓÃÎÞÅþÁ¬Ã¸µÄÑÆÁå̽ÕëºÍ¸ßѸËٶȵÄCRISPR/Cas12aÐźÅÊä³ö²ßÂÔ£¬£¬£¬£¬£¬ÊµÏÖÁËÔÚ30·ÖÖÓÄÚ¶ÔmiRNAµÄ¸ß¾«¶È¶¨Á¿ÆÊÎö¡£¡£¡£¡£¡£¡£Ñо¿ÍŶÓͨ¹ýÁÙ´²Ñù±¾ÑéÖ¤Á˸ü¼ÊõµÄÓÐÓÃÐÔ£¬£¬£¬£¬£¬·¢Ã÷miR-200aºÍmiR-126Ôڷΰ©×éÖ¯Öеıí´ïˮƽÏÔÖø½µµÍ£¬£¬£¬£¬£¬ÇҸü¼ÊõÓë¹Å°åÒªÁìЧ¹ûÒ»Ö¡£¡£¡£¡£¡£¡£DBmRCA¼¼Êõ¾ßÓÐʱ¼äЧÂʸߡ¢Ñ¸ËÙ¶ÈÇ¿ºÍ²Ù×÷Á÷³Ì¼ò»¯µÈÓŵ㣬£¬£¬£¬£¬ÎªÁÙ´²miRNAÆÊÎöÌṩÁËÒ»ÖÖ¿É¿¿µÄ¹¤¾ß£¬£¬£¬£¬£¬ÓÐÍûÖúÁ¦·Î°©µÄÔçÆÚÕï¶ÏºÍÖÎÁÆ¡£¡£¡£¡£¡£¡£

ͼ½âÕªÒª
FAQ
Ò»Ñùƽ³£CRISPRÏà¹ØÊÔ¼ÁÒÔ¼°CasÂѰ׿ÉÒÔ´æ·Å¶à¾Ã£¿£¿£¿£¿
¢ÙRPAºãÎÂÀ©ÔöÊÔ¼ÁºÐÓÚ-20¡æÉúÑÄ£¬£¬£¬£¬£¬¿Éºã¾Ã´æ·Å¡£¡£¡£¡£¡£¡£
¢Ú°Ð±êÖÊÁ£¿£¿£¿£¿Éºã¾Ã´æ·Å-20¡æ ¢Û CasÂѰ×ÖØ¸´¶³ÈÚÈÝÒ×Ó°Ïì»îÐÔ£¬£¬£¬£¬£¬½¨Òé·Ö×°¶à¹Ü£¬£¬£¬£¬£¬´æ·Å-80¡æ£¬£¬£¬£¬£¬Æ¾Ö¤ÊµÑéÐèҪȡ³öʹÓᣡ£¡£¡£¡£¡£ÁíÍ⣬£¬£¬£¬£¬¶ÌÆÚÄÚʹÓõ쬣¬£¬£¬£¬¿É·Å-20¡æÉúÑÄ¡£¡£¡£¡£¡£¡£
¢ÛcrRNAÈÝÒ×½µ½â£¬£¬£¬£¬£¬½¨Òé¶Ìʱ¼äÄÚÓò»µ½µÄÓÚ-80¡æÉúÑÄ¡£¡£¡£¡£¡£¡£
¢Ü̽ÕëÊÇDNAË«Á´£¬£¬£¬£¬£¬Ïà¶ÔÀ´ËµÃ»ÓÐÄÇôÈÝÒ×½µ½â£¬£¬£¬£¬£¬¿É·Å-20¡æÉúÑÄ¡£¡£¡£¡£¡£¡£
Cas9¡¢Cas12ºÍCas13ÈýÕßÖ®¼äÓÐÊ²Ã´Çø±ð£¿£¿£¿£¿
Cas12Óëguide RNA¡¢target DNAÁ¬Ïµºó»á±»Òý·¢Õë¶ÔssDNAµÄ·´Ê½¼ôÇлîÐÔ£»£»£»£»£»Cas13Óëguide RNA¡¢target RNAÁ¬Ïµºó»á±»Òý·¢Õë¶ÔssRNAµÄ·´Ê½¼ôÇлîÐÔ£»£»£»£»£»¶øCas9ÔÝδ±»±¨µÀ·´Ê½¼ôÇлîÐÔ¡£¡£¡£¡£¡£¡£
ÍêÃÀÕæÈË